Introduction. Interleukin 10 (IL-10) is anti-inflammatory cytokine that plays central regulatory role in immune-mediated inflammation caused by viral infection. The purpose of this work was to study the action of IL10 on the efficiency of cell therapy in a mouse model of influenza pneumonia.
Methodology. We used an experimental model of influenza pneumonia obtained by intranasal infection of white non-inbred mice weighing 14-18 grams with influenza virus A / FM / 1/47 / H1N1. The virus was adapted to the lung tissue of mice, infectious titer - 4.0 lg ID50, hemagglutinin titer 1:256 GAO/0.2 ml. The recombinant human interleukin-10 expressed in E.coli was used in the study. For cell transplantation human umbilical cord MSCs were used. Transplantation have been performed with native MSCs, MSCs pretreated with human interleukin 10, and MSCs transfected with a plasmid containing the IL10 gene. The study used several groups of animals that were injected with different doses of IL-10 and 200,000 MSCs. Mouse lung morphometry and histology have been studied.
Results. It was shown that the efficiency index of intravenous and intraperitoneal administration of IL-10 (concentration 1mkg/100 mkl) was 40-60%. Survival rate of infected animals after introduction of IL-10 followed by transplantation of MSCs native, transfected and primed with IL-10 have been increased to 80%. The infectious titer of the virus in the lung tissue decreased by 2-4 lg ID50 compared to control animals. There were no signs of exudative serous-hemorrhagic inflammation in the surviving experimental animals in the immediate and long-term periods (8-22 days).
Conclusion. As a result of the studies, it was shown that intravenous administration of IL-10 at a concentration of 1mkg/100 mkl and transplantation of primed and transfected MSCs exhibited a substantial therapeutic effect, increased the survival rate of mice up to 60-80%, and inhibited the reproduction of influenza virus in the lung tissue by 2-4 lg ID50.